Search Results - "Chandiwana, Nomathemba"

Refine Results
  1. 1
  2. 2

    Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications by Chandiwana, Nomathemba C, Siedner, Mark J, Marconi, Vincent C, Hill, Andrew, Ali, Mohammed K, Batterham, Rachel L, Venter, Willem Daniel Francois

    “…Abstract Rapid advances in the potency, safety, and availability of modern HIV antiretroviral therapy (ART) have yielded a near-normal life expectancy for most…”
    Get full text
    Journal Article
  3. 3

    Impact of long-acting therapies on the global HIV epidemic by Chandiwana, Nomathemba C., Serenata, Celicia M., Owen, Andrew, Rannard, Steve, Pérez Casas, Carmen, Scott, Cherise, Hill, Andrew, Clayden, Polly, Flexner, Charles

    Published in AIDS (London) (15-12-2021)
    “…Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV…”
    Get full text
    Journal Article
  4. 4

    Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens by Cindi, Zinhle, Maartens, Gary, Bradford, Yuki, Venter, Willem D.F., Sokhela, Simiso, Chandiwana, Nomathemba C., Haas, David W., Sinxadi, Phumla

    “…Excessive weight gain affects some HIV-positive individuals prescribed dolutegravir-containing regimens. Mechanisms underlying such weight gain are unknown…”
    Get full text
    Journal Article
  5. 5

    Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa by Chandiwana, Nomathemba C., Chersich, Matthew, Venter, W.D. François, Akpomiemie, Godspower, Hill, Andrew, Simmons, Bryony, Lockman, Shahin, Serenata, Celicia M., Fairlie, Lee, Moorhouse, Michelle A.

    Published in AIDS (London) (02-02-2021)
    “…OBJECTIVE:Dolutegravir exposure at conception was associated with a preliminary signal of increased infant neural tube defect (NTD) risk. As low maternal…”
    Get full text
    Journal Article
  6. 6

    Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans by Mateza, Somila, Bradford, Yuki, Maartens, Gary, Sokhela, Simiso, Chandiwana, Nomathemba C., Venter, Willem D.F., Post, Frank A., Ritchie, Marylyn D., Haas, David W., Sinxadi, Phumla

    Published in Pharmacogenetics and genomics (01-07-2023)
    “…Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV by Mondleki, Enkosi, Banda, Clifford G, Chandiwana, Nomathemba C, Sokhela, Simiso, Wiesner, Lubbe, Venter, Francois, Maartens, Gary, Sinxadi, Phumla Z

    “…Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle income countries by Steegen, Kim, Chandiwana, Nomathemba, Sokhela, Simiso, Venter, Willem DF, Hans, L

    Published in AIDS (London) (06-02-2023)
    “…Baseline rilpivirine drug resistance mutations (DRM) are a risk factor for virological failure in patients treated with long-acting cabotegravir plus…”
    Get full text
    Journal Article